nilutamide has been researched along with imidazolidines in 219 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 54 (24.66) | 18.7374 |
| 1990's | 93 (42.47) | 18.2507 |
| 2000's | 50 (22.83) | 29.6817 |
| 2010's | 18 (8.22) | 24.3611 |
| 2020's | 4 (1.83) | 2.80 |
| Authors | Studies |
|---|---|
| Akimoto, S; Higa, T; Isaka, S; Masai, M; Shimazaki, J | 1 |
| Berger, V; Berson, A; Chachaty, C; Fau, D; Fromenty, B; Pessayre, D; Wolf, C | 2 |
| Gordon, DA; Miesfeld, RL; Rundlett, SE | 1 |
| Berson, A; Eugene, D; Fau, D; Fisch, C; Fromenty, B; Pessayre, D | 1 |
| Braud, ML; Camus, P; Coudert, B; Foucher, P; Gabez, P; Lacroix, S; Mabille, JP; Pfitzenmeyer, P; Piard, F | 1 |
| Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, M | 1 |
| Camus, P; Coudert, B; D'Athis, P; Delchambre, J; Dupront, A; Foucher, P; Jeannin, L | 1 |
| Boccardo, F; Decensi, AU; Fioretto, L; Giuliani, L; Guarneri, D; Macaluso, MP; Martorana, G; Mini, E; Periti, P; Santi, L | 1 |
| Horsmans, Y; Lannes, D; Larrey, D; Letteron, P; Loeper, J; Pessayre, D; Tinel, M | 1 |
| Campus, G; D'Atri, M; De Lisa, A; Migliari, R; Scarpa, RM; Serra, A; Usai, E; Zucca, I | 1 |
| Boccardo, F; Decensi, A; Guarneri, D; Lalanne, JM; Merlo, F; Paoletti, MC | 1 |
| Denis, L | 1 |
| Boccardo, F; Costantini, M; Decensi, AU; Giuliani, L; Guarneri, D; Martorana, G; Paoletti, MC; Positano, N | 1 |
| Mora, G; Muldoon, TG; Steinsapir, J | 1 |
| Akaza, H; Akimoto, S; Aso, Y; Fuse, H; Imai, K; Izaka, S; Kihara, K; Niijima, T; Shimazaki, J; Yamanaka, H | 1 |
| Crawford, ED; Nabors, WL | 1 |
| Cantwell, BM; Carmichael, J; Dowsett, M; Harris, AL; Millward, MJ | 1 |
| Benoit, G; Bismuth, E; Buffet, C; Ducreux, M; Etienne, JP; Hammel, P; Ladouch-Badre, A | 1 |
| Pavone-Macaluso, M | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Tewari, HD; Trachtenberg, J; Venner, PM | 2 |
| Creaven, PJ; Pendyala, L; Tremblay, D | 1 |
| Du Plessis, DJ | 1 |
| Beland, G | 1 |
| Brand, T; Slob, AK | 1 |
| Schröder, FH | 2 |
| Bolt, J; Mulder, E; Schuurmans, AL; Veldscholte, J | 1 |
| Debruyne, FM; Dijkman, GA; Fernandez del Moral, P; Mulders, PF; Theeuwes, AG | 1 |
| Cacciatore, M; Cavallo, N; Daricello, G; Pavone, C; Pavone-Macaluso, M; Romano, C; Serretta, V | 1 |
| Caty, A; Couette, JE; Douchez, J; Droz, JP; Kerbrat, P; Namer, M; Toubol, J | 1 |
| Dieudonne, MN; Giudicelli, Y; Leneveu, MC; Pecquery, R | 1 |
| Akoun, GM; Gauthier-Rahman, S; Kuntz, D; Liote, F; Liote, HA | 1 |
| Dhar, JD; Setty, BS | 2 |
| Cacciatore, M; Daricello, G; Pavone, C; Pavone-Macaluso, M; Serretta, V | 1 |
| Namer, M | 1 |
| Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H | 1 |
| Furr, BJ | 2 |
| Daricello, G; Pavone, C; Pavone-Macaluso, M; Romano, C; Serretta, V | 1 |
| Asscheman, H; Gooren, LJ; Peereboom-Wynia, JD | 1 |
| Biedermann, C; Bolle, JF; Hering, F; Hodel, T; Knönagel, H; Neuenschwander, H; Senn, E | 1 |
| Brailly, S; Couzinet, B; Schaison, G; Thalabard, JC; Thomas, G | 1 |
| Cohen, L; Cohen-Kettenis, PT; Gooren, LJ; van Kemenade, JF | 1 |
| de Jong, FH; Lamberts, SW; Uitterlinden, P | 1 |
| Babany, G; Berson, A; Freneaux, E; Larrey, D; Letteron, P; Pessayre, D; Tinel, M | 1 |
| Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE | 1 |
| Huot, RI; Shain, SA | 2 |
| Ayub, M; Levell, MJ | 1 |
| Dupront, A; Meyer, BH; Pottier, J; Tremblay, D | 1 |
| Bouman, FG; de Voogt, HJ; Geldof, AA; Gooren, LJ; Rao, BR | 2 |
| Bruchovsky, N; Fletcher, T; Foekens, JA; Goldenberg, SL; Lawson, D; Rennie, PS | 1 |
| Abreu, LC; Hayashi, H; Picarelli, ZP; Porto, CS | 1 |
| Fiet, J; Moguilewsky, M; Raynaud, JP; Tournemine, C | 1 |
| Amiel, J; Namer, M; Toubol, J | 1 |
| Gooren, L; Hoogslag, M; Rao, BR; Smals, A; Spijkstra, JJ; Spinder, T; van Kessel, H | 1 |
| Bélanger, A; Brun, D; Dupont, A; Gagné, C; Giguère, M; Labrie, F; Lupien, PJ; Moorjani, S | 1 |
| Cotard, M; Moguilewsky, M; Proulx, L; Raynaud, JP; Tournemine, C | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Tewari, HD; Venner, PM | 1 |
| Navratil, H | 1 |
| Hubert, J; Lamy, P; Seigneur, J; Trechot, PF | 1 |
| Moguilewsky, M; Tournemine, C | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Trachtenberg, J; Venner, PM | 1 |
| Boccon-Gibod, L; Botto, H; Brisset, JM; Camey, M; Cariou, G; Duclos, JM; Duval, F; Gontiès, D; Jorest, R; Lamy, L | 1 |
| Bertagna, C; Hucher, M; Moguilewsky, M | 1 |
| Fiet, J; Le Goff, JM; Martin, PM; Moguilewsky, M; Ojasoo, T; Raynaud, JP | 1 |
| Bertagna, C; Creaven, PJ; Huben, R; Pendyala, L; Tremblay, D | 1 |
| de Voogt, HJ; Geldof, AA; Rao, BR; van der Wilt, CL | 1 |
| Bertagna, C; Brisset, JM; Proulx, L | 1 |
| Bertagna, C; Creaven, PJ; Huben, R; Mouren, M; Pendyala, L; Tremblay, D | 1 |
| Dupont, A; Harnois, C; Labrie, F; Malenfant, M | 1 |
| Burton, S; Trachtenberg, J | 1 |
| Coussediere, D; Labrie, F; Moguilewsky, M; Pottier, J; Raynaud, JP | 1 |
| Bertagna, C; Coussedière, D; Husson, JM; Moguilewsky, M; Pendyala, L; Pottier, J; Raynaud, JP; Salmon, J; Tournemine, C; Tremblay, D | 1 |
| Bélanger, A; Dupont, A; Labrie, F | 1 |
| Bélanger, A; Cusan, L; Kelly, PA; Labrie, F; Raynaud, JP; Séguin, C | 1 |
| Bélanger, A; Bonne, C; Labrie, F; Lefebvre, FA; Moguilewsky, M; Raynaud, JP | 1 |
| Belanger, A; Cusan, L; Dupont, A; Fazekas, AT; Husson, JM; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lefebvre, FA; Monfette, G; Raynaud, JP | 1 |
| Belanger, A; Dupont, A; Fazekas, AT; Gareau, J; Husson, JM; Labrie, F; Lacoursiere, Y; Monfette, G; Raynaud, JP; Sandow, J | 1 |
| Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M | 1 |
| Belanger, A; Dupont, A; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Bélanger, A; Dupont, A; Emond, J; Labrie, F; Monfette, G | 1 |
| Brown, TR; Migeon, CJ; Rothwell, SW; Sultan, C | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lacourciere, Y; Monfette, G; Raynaud, JP | 1 |
| Kopu, H | 1 |
| Pandha, H; Waxman, J | 1 |
| Deboel, L; Heyns, W; Hoeben, E; Rombauts, L; Rosseels, J; Swinnen, J; Vanderhoydonc, F; Verhoeven, G | 1 |
| Debruyne, FM; Dijkman, GA; Fernandez del Moral, P; Janknegt, RA | 1 |
| Abbou, CC; Bartoletti, R; Bernstein-Hahn, L; Bracken, B; Brisset, JM; Chisholm, G; Crawford, ED; Da Silva, FC; Debruyne, FM; Janknegt, RA | 1 |
| Akimoto, S; Kitagawa, N; Masai, M; Nakamura, T; Shimazaki, J | 1 |
| Chatelain, C; Cosaert, J; Rousseau, V | 1 |
| Bentel, JM; Birrell, SN; Hickey, TE; Horsfall, DJ; Ricciardelli, C; Tilley, WD; Weger, MA | 1 |
| Berson, A; Deschamps, D; Fau, D; Fisch, C; Fromenty, B; Pessayre, D; Schmets, L; Wolf, C | 1 |
| Decensi, A; Fontana, V; Torrisi, R | 1 |
| Govindan, MV; Koutsilieris, M; Pagé, N; Warriar, N | 2 |
| Braf, Z; Matzkin, H | 1 |
| Bertagna, C; De Géry, A; François, JP; Hucher, M; Zanirato, J | 1 |
| Boccardo, F; Decensi, A; Fontana, V; Guarneri, D; Marroni, P; Minuto, F; Padovani, P; Torrisi, R | 1 |
| Benhamou, JP; Bernuau, J; Bertheau, P; Degott, C; Durand, F; Gerbal, JL; Hammel, P; Huc, D; Pescatore, P | 1 |
| de Gery, A; Gaillard-Moguilewsky, M; Ulmann, A | 1 |
| Janknegt, RA | 1 |
| Bertagna, C; de Gery, A; Hucher, M | 1 |
| Doré, JC; Fiet, J; Gô, AL; Ojasoo, T; Raynaud, JP | 1 |
| Boccardo, F; Decensi, A; Marroni, P; Padovani, P; Pensa, F; Torrisi, R | 1 |
| McLeod, DG | 1 |
| Matzkin, H; Soloway, MS | 1 |
| Benassayag, E | 1 |
| Barritault, D; Caruelle, D; Caruelle, JP; Courty, J; Delbe, J; Laaroubi, K; Vacherot, F | 1 |
| Abbou, CC; Barthélémy, Y; Chopin, D; Colombel, M; Gasman, D; Patard, JJ | 1 |
| Aboutaeib, R; Benjelloun, S; el Moussaoui, A; Joual, A; Rabii, R | 1 |
| Doermann, F; Godart, D; Marty, F; Mérillon, H | 1 |
| Dole, EJ; Holdsworth, MT | 1 |
| Kaisary, AV | 1 |
| Abbou, CC; de Gery, A; Janknegt, RA; Smith, JA | 1 |
| Labrie, F; Simard, J; Singh, SM | 1 |
| Gerridzen, RG; Huan, SD; Stewart, DJ; Yau, JC | 1 |
| Abbou, CC; deGery, A; Janknegt, RA; Lange, PH; Smith, JA | 1 |
| Gomella, LG; Ismail, M; Nathan, FE | 1 |
| De Reijke, TM; Debruyne, FM; Dijkman, GA; Janknegt, RA | 1 |
| Akakura, K; Akimoto, S; Inomiya, H; Ito, H; Shimazaki, J | 1 |
| Dijkman, GA; Diokno, AC; Klotz, LH; Zippe, CD | 1 |
| Bleiberg, H; Buset, M; Cervantes, A; Cirera, L; De Greve, J; Duez, N; Gay, F; Grimaldi, C; Kok, TC; Messner, M; Nitti, D; Paillot, B; Rougier, P; Sahmoud, T; Wils, J | 1 |
| Eastham, JA; Sartor, O | 1 |
| Lansiaux, P | 1 |
| Abbou, CC; Leblanc, V; Lucas, C | 1 |
| Boccon-Gibod, L | 1 |
| Battmann, T; Bouchoux, F; Branche, C; Cerede, E; Gaillard-Kelly, M; Goubet, F; Philibert, D; Teutsch, G | 1 |
| Denis, L; Mahler, C; Verhelst, J | 1 |
| Soloway, MS; Wieder, JA | 1 |
| Bonnet, P | 1 |
| Chatelain, C; Fourcade, RO | 1 |
| Balk, SP; Bubley, GJ; Fenton, MA; Fertig, AM; Kolvenbag, G; Shuster, TD; Taplin, ME | 1 |
| Crook, JM; Huan, S; Malone, S; Segal, R; Szumacher, E | 1 |
| Bentel, JM; Birrell, SN; Holds, DJ; Horsfall, DJ; Pickering, MA; Tilley, WD | 1 |
| Sarosdy, MF | 1 |
| De Angelis, M; De Benedetto, G; Migliari, R; Murru, M; Muscas, G; Verdacchi, T | 1 |
| Candas, B; Labrie, F | 1 |
| Iversen, P; Melezinek, I; Schmidt, A | 1 |
| Bennett, CL; Crawford, ED; DeMasi, V; Sartor, O; Schellhammer, PF; Schmitt, B; Wilt, TJ | 1 |
| Bishop, TC; Dalton, JT; Kirkovsky, L; Marhefka, CA; Miller, DD; Moore, BM; Mukherjee, A | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Iversen, P; Kolvenbag, GJ; Newling, DW | 1 |
| Shain, SA | 1 |
| Desai, A; Stadler, WM; Vogelzang, NJ | 1 |
| Kaajan, JP; van der Drift, MA | 1 |
| Blackmore, TK; Eaton, VS | 1 |
| de Reijke, T; Derobert, E | 1 |
| Iversen, P | 1 |
| Bennett, CL; Raisch, DW; Sartor, O | 1 |
| Dalton, JT; He, Y; Hong, SS; Kirkovsky, L; Marhefka, C; Miller, DD; Perera, MA; Stourman, N; Yin, D | 1 |
| Anderson, J | 1 |
| Aprikian, AG; Kassouf, W; Tanguay, S | 1 |
| Ask, K; Boucher, JL; Camus, P; Casse, L; Dijols, S; Frapart, YM; Giroud, C; Kim, KS; Mansuy, D; Sari, MA; Stuehr, DJ | 1 |
| Edouard, A; Escarmant, P; Lombard, F; Lorinet, C; Rat, C; Robinel, R | 1 |
| Cardi, A; Di Silverio, F; Sciarra, A | 1 |
| Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N | 1 |
| Artur, Y; Asare, N; Ask, K; Camus, P; Décologne, N; Holme, JA; Pelczar, H | 1 |
| Lehtovuori, PT; Nyrönen, TH; Söderholm, AA | 1 |
| Chander, S; Cheung, P; Choo, R; Danjoux, C; Deboer, G; Loblaw, A; Morton, G; Pearce, A; Szumacher, E; Woo, T | 1 |
| Debré, B; Delongchamps, NB; Peyromaure, M; Zerbib, M | 1 |
| Arlen, PM; Bastian, A; Beetham, P; Dahut, W; Grosenbach, DW; Gulley, JL; Lieberman, R; Marte, J; Morin, S; Schlom, J; Steinberg, SM; Todd, N; Tsang, KY | 1 |
| Crook, J; Dahrouge, S; Malone, S; Perry, G; Segal, R | 1 |
| Bian, Q; Chen, JF; Song, L; Sun, H; Wang, XR; Xu, LC | 1 |
| Cazaban, A; Chéreau, O; Somogyi, A; Zuech, P | 1 |
| Kantoff, PW; Lifsey, D; Nakabayashi, M; Oh, WK; Regan, MM; Sartor, O; Taplin, ME | 1 |
| Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Bai, CX; Furukawa, T; Kurokawa, J; Nakaya, H; Tamagawa, M | 1 |
| Ask, K; Boucher, JL; Camus, P; Décologne, N; Ginies, C; Holme, JA; Låg, M; Pelczar, H | 1 |
| Asaka, J; Inui, K; Katsura, T; Okuda, M; Terada, T | 1 |
| Chang, CY; Chang, SY; Hsuuw, YD; Huang, CK; Huang, FJ; Huang, KE; Kang, HY; Shyr, CR | 1 |
| Chen, JF; Cui, LB; Hong, X; Song, L; Sun, H; Wang, XR; Xu, LC; Xu, XL | 1 |
| Boelsterli, UA; Ho, HK; Leow, KY; Zhou, S | 1 |
| Akishita, M; Eto, M; Kaneko, A; Okabe, T; Ouchi, Y; Yu, J | 1 |
| Agarwal, A; Pahalajani, G; Raina, R; Zippe, C | 1 |
| Hara, S; Hyochi, N; Isaacs, JT; Ishioka, J; Kageyama, Y; Kihara, K; Singh, P; Urushibara, M | 1 |
| Dong, Z; Lu, S; Wang, A | 1 |
| Dalton, JT; Farrar, WL; Hamel, E; Hossain, MT; Jones, A; Kane, CT; Lill, MA; Risbood, P; Sharifi, N | 1 |
| Brulé, E; Jaouen, G; McGlinchey, MJ; Müller-Bunz, H; Payen, O; Plamont, MA; Top, S; Vessières, A | 1 |
| Chapman, RA; Crawford, ED; Eisenberger, MA; Fontana, JA; Hussain, MH; Mills, GM; Parab, M; Raghavan, D; Sartor, AO; Tangen, CM | 1 |
| Chan, P; Odel, JG | 1 |
| Arlen, PM; Dahut, WL; Gulley, JL; Liewehr, DJ; Madan, RA; Schlom, J; Steinberg, SM | 1 |
| Adler, DG; Kabbani, W; Merwat, SN | 1 |
| Brower, V | 1 |
| Cheung, P; Choo, R; Danjoux, C; Gardner, S; Loblaw, DA; Morton, G; Pearse, M; Szumacher, E | 2 |
| Akishita, M; Eto, M; Kato, S; Ogawa, S; Okabe, T; Ouchi, Y; Son, BK; Yu, J | 1 |
| Hashimoto, R; Koizumi, H; Okabe, T; Ouchi, Y; Yu, J | 1 |
| Keiser, J; Vargas, M; Vennerstrom, JL | 1 |
| Hu, JX; Li, J; Li, YF; Pan, C; Wang, HM; Xu, LC; Zhang, JP | 1 |
| Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F | 1 |
| Dong, Y; Guy, RK; Keiser, J; Lin, MF; Min, J; Muniyan, S; Vargas, M; Vennerstrom, JL; Wang, C; Wang, X; Zhao, Q | 1 |
| Brancaleone, V; Bucci, M; Cirino, G; d'Emmanuele di Villa Bianca, R; Esposito, F; Ianaro, A; Matassa, DS; Sorrentino, R; Vellecco, V | 1 |
| Borkar, RM; Raju, B; Raju, G; Ramesh Babu, A; Srinivas, R | 1 |
| Bussy, U; Chung-Davidson, YW; Li, K; Li, W | 1 |
| Altenburger, R; Baldauf, L; Fetter, E; Lidzba, A; Scholz, S; Schüttler, A; Smetanová, S | 1 |
| Brito, H; Lourenço, EP; Nzwalo, H; Sampaio, MR | 1 |
| Ajmal Ali, M; Al-Hemaid, FMA; Chen, SM; Elangovan, A; Elshikh, MS; Karthik, R; Muthukrishnan, P; Muthuraj, V; Sasikumar, R; Vinoth Kumar, J | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| Anwar, S; Gourinath, S; Jain, SK; Sahar, T; Vijayan, R; Wajid, S; Waziri, F | 1 |
| Chhabra, M; Rashid, M; Shamshavali, K | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
| Bolla, RS; Gandikota, NM; Kasi Viswanath, IV | 1 |
| Chen, SM; Karthik, R; Kokulnathan, T; Kumar, JV; Sakthinathan, S | 1 |
| Gu, J; Gu, L; Lian, D; Liu, X; Zheng, Y; Zhou, W | 1 |
| Chauhan, G; Gupta, S; Mehta, A | 1 |
| Bao, J; He, X; Pan, X; Qi, Y; Shao, G; Zhang, JZH | 1 |
| Balasubramanian, S; Drozd, KV; Gruzdev, MS; Perlovich, GL; Prashanth, J; Surov, AO; Voronin, AP | 1 |
39 review(s) available for nilutamide and imidazolidines
| Article | Year |
|---|---|
Pharmacokinetics and metabolism of nilutamide.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Animals; Biological Availability; Dogs; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Random Allocation; Rats; Reference Values | 1991 |
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Topics: Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1991 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; Erectile Dysfunction; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Italy; Libido; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Quality of Life; Testosterone | 1990 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Puberty, Precocious; Skin Diseases; Spironolactone | 1988 |
Androgen blockade and suppression for prostate carcinoma.
Topics: Androgen Antagonists; Cyproterone; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1989 |
What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
Topics: Androgen Antagonists; Animals; Buserelin; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Steroid | 1987 |
Proliferation of AXC/SSh rat prostate cancer cells in vitro is androgen modulated.
Topics: Animals; Cell Division; Clone Cells; Imidazoles; Imidazolidines; Male; Mitogens; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats; Receptors, Androgen; Testosterone; Tumor Cells, Cultured | 1987 |
Pharmacological and clinical studies of the antiandrogen Anandron.
Topics: Androgen Antagonists; Animals; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Testosterone | 1987 |
Design of antiandrogens and their mechanisms of action: a case study (anandron).
Topics: Androgen Antagonists; Androgens; Animals; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Receptors, Androgen | 1987 |
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Topics: Androgen Antagonists; Androgens; Animals; Drug Therapy, Combination; Feedback; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; In Vitro Techniques; Luteinizing Hormone; Male; Organ Size; Prostatic Neoplasms; Receptors, Androgen | 1984 |
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms | 1983 |
[Complete androgen blockage in the treatment of metastatic prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Prostatic Neoplasms | 1994 |
Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Odds Ratio; Orchiectomy; Prostate; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1994 |
Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1993 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1993 |
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1993 |
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Flutamide; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Structure-Activity Relationship; Tosyl Compounds | 1997 |
[Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996].
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Imidazoles; Imidazolidines; Lymph Node Excision; Male; Polymerase Chain Reaction; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Rats | 1997 |
Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 1998 |
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
The place and the results of monotherapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Antiandrogens as monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
Topics: Aged; Androgen Antagonists; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2000 |
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Sexuality; Tosyl Compounds | 2001 |
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 2001 |
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2001 |
[Respiratory side-effects of drugs].
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antineoplastic Agents; Bleomycin; Bronchoalveolar Lavage Fluid; Diagnosis, Differential; Female; Humans; Imidazoles; Imidazolidines; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Nitrofurantoin; Pulmonary Fibrosis; Radiography; Respiratory Function Tests | 2002 |
Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Double-Blind Method; Factor Analysis, Statistical; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Antiandrogen monotherapy: indications and results.
Topics: Aged; Androgen Antagonists; Anilides; Castration; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Patient Compliance; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2002 |
The role of antiandrogen monotherapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Patient Compliance; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2004 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Progesterone Congeners; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Tosyl Compounds | 2004 |
Bioactivation and hepatotoxicity of nitroaromatic drugs.
Topics: Benzophenones; Biotransformation; Chemical and Drug Induced Liver Injury; Flutamide; Imidazolidines; Nifedipine; Nitro Compounds; Nitrofurantoin; Nitrophenols; Sulfonamides; Tolcapone | 2006 |
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms | 2013 |
Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis.
Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Imidazolidines; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
44 trial(s) available for nilutamide and imidazolidines
| Article | Year |
|---|---|
A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1992 |
Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vision Disorders | 1991 |
Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Estradiol; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Testosterone | 1991 |
[Clinical study of RU 23908 (nilutamide) in prostatic cancer].
Topics: Administration, Oral; Androgen Antagonists; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1991 |
Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Estradiol; Female; Follicle Stimulating Hormone; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Menopause; Middle Aged; Sex Hormone-Binding Globulin | 1991 |
Total androgen ablation: Canadian experience.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1991 |
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Topics: Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1991 |
Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
Topics: Acid Phosphatase; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Pain; Prostatic Neoplasms; Survival Rate | 1991 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Testosterone | 1990 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; Erectile Dysfunction; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Italy; Libido; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Quality of Life; Testosterone | 1990 |
A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Pain; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Topics: Actuarial Analysis; Aged; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1990 |
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1989 |
[Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1989 |
Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease.
Topics: Adult; Androgen Antagonists; Female; Gonadal Steroid Hormones; Gonadotropins; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Ovulation; Polycystic Ovary Syndrome | 1989 |
Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
Topics: Aged; Androgen Antagonists; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; France; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prostatic Neoplasms; Random Allocation; Remission Induction | 1988 |
Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 1987 |
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
Total androgen blockade for metastatic cancer of the prostate.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prognosis; Prostatic Neoplasms; Random Allocation; Remission Induction | 1988 |
Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
Topics: Aged; Androgen Antagonists; Clinical Trials as Topic; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 1987 |
Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Double-Blind Method; Humans; Hydronephrosis; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate; Urethral Obstruction | 1995 |
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Topics: Acid Phosphatase; Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis | 1993 |
French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1994 |
Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Erythrocyte Count; Erythropoiesis; Hematocrit; Hemoglobins; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Platelet Count; Prostatic Neoplasms; Regression Analysis; Testosterone; Triptorelin Pamoate | 1994 |
Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1993 |
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Buserelin; Double-Blind Method; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prostatic Neoplasms | 1993 |
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Androstenedione; Antineoplastic Agents; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Triptorelin Pamoate | 1994 |
[Indications of antiandrogens in benign hyperplasia of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Hyperplasia | 1995 |
Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Castration; Humans; Hydronephrosis; Imidazoles; Imidazolidines; Leuprolide; Male; Prospective Studies; Prostatic Neoplasms; Urination Disorders | 1997 |
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Multivariate Analysis; Orchiectomy; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors | 1997 |
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Topics: Actuarial Analysis; Androgen Antagonists; Combined Modality Therapy; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors | 1997 |
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Liver Neoplasms; Male; Survival Rate; Triptorelin Pamoate | 1998 |
[Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Data Interpretation, Statistical; Drug Tolerance; Humans; Imidazoles; Imidazolidines; Injections, Intramuscular; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Time Factors; Triptorelin Pamoate | 1997 |
Intermittent androgen suppression in the management of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Prostatic Neoplasms | 1999 |
Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Double-Blind Method; Factor Analysis, Statistical; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cancer Vaccines; Disease Progression; Humans; Imidazolidines; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms | 2005 |
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Treatment Outcome | 2005 |
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Failure | 2005 |
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Leuprolide; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2007 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Free Survival; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Survival Rate; Tosyl Compounds | 2008 |
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Castration; Combined Modality Therapy; Follow-Up Studies; Humans; Imidazolidines; Kaplan-Meier Estimate; Male; Middle Aged; Poxviridae; Prostatic Neoplasms | 2008 |
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Salvage Therapy; Survival Rate; Time Factors | 2009 |
140 other study(ies) available for nilutamide and imidazolidines
| Article | Year |
|---|---|
Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Combined Modality Therapy; Estrogens; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Orchiectomy; Osteoblasts; Osteolysis; Osteosclerosis; Prostatic Neoplasms; Radiography; Treatment Outcome | 1992 |
Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen.
Topics: Androgen Antagonists; Animals; Free Radicals; Humans; Hydrogen Peroxide; Imidazoles; Imidazolidines; Lung; Lung Diseases; Male; Microsomes; NADP; Nitro Compounds; Oxidation-Reduction; Oxygen Consumption; Rats; Rats, Inbred Strains; Superoxides | 1992 |
Characterization of a panel of rat ventral prostate epithelial cell lines immortalized in the presence or absence of androgens.
Topics: Acid Phosphatase; Androgen Antagonists; Animals; Antigens, Polyomavirus Transforming; Blotting, Western; Cell Line; Cell Line, Transformed; Chloramphenicol O-Acetyltransferase; Culture Techniques; Epithelial Cells; Epithelium; Imidazoles; Imidazolidines; Karyotyping; Male; Metribolone; Orchiectomy; Polymerase Chain Reaction; Prostate; Rats; Rats, Sprague-Dawley; Receptors, Androgen; RNA, Messenger; Simian virus 40; Testosterone; Transfection | 1992 |
Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Glutathione; Glutathione Disulfide; Imidazoles; Imidazolidines; L-Lactate Dehydrogenase; Liver; Male; Oxidation-Reduction; Oxygen Consumption; Rats; Rats, Sprague-Dawley | 1992 |
Nilutamide pneumonitis: a report on eight patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Lung; Male; Middle Aged; Prostatic Neoplasms; Pulmonary Fibrosis; Treatment Outcome | 1992 |
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Liver Diseases; Male; Prostatic Neoplasms; Pulmonary Fibrosis | 1992 |
Pharmacokinetics and metabolism of nilutamide in the isolated rat lung.
Topics: Androgen Antagonists; Animals; Chromatography, High Pressure Liquid; Female; Imidazoles; Imidazolidines; Lung; Male; Perfusion; Rats; Rats, Inbred Strains | 1991 |
Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.
Topics: Androgen Antagonists; Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Female; Ferricyanides; Humans; Hydroxylation; Imidazoles; Imidazolidines; Male; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Rats; Rats, Inbred Strains; Troleandomycin | 1991 |
Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vision, Ocular | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide.
Topics: Androgen Antagonists; Animals; Cells, Cultured; Electron Spin Resonance Spectroscopy; Free Radicals; Glutathione; Glutathione Disulfide; Imidazoles; Imidazolidines; Male; Microsomes, Liver; Oxidation-Reduction; Oxygen Consumption; Rats; Rats, Inbred Strains | 1991 |
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Topics: Androgen Antagonists; Antineoplastic Agents; Carcinoma; Drug Evaluation; Drug Tolerance; Humans; Imidazoles; Imidazolidines; Italy; Lymphatic Metastasis; Male; Prostatic Neoplasms; Remission Induction; Survival Rate; Tablets; Time Factors | 1991 |
Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Topics: Androgen Antagonists; Animals; Cycloheximide; Flutamide; Imidazoles; Imidazolidines; Kinetics; Male; Prostate; Rats; Receptors, Androgen | 1991 |
Total androgen ablation: American experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1991 |
[Nilutamide-induced acute hepatitis].
Topics: Acute Disease; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1991 |
Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
Topics: Androgen Antagonists; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone | 1991 |
Anandron: a new step in the treatment of advanced prostate cancer. Proceedings of a symposium. June 12, 1989.
Topics: Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1991 |
On the organization of partner preference behavior in female Wistar rats.
Topics: Androgen Antagonists; Animals; Copulation; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Female; Flutamide; Imidazoles; Imidazolidines; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Inbred Strains; Sex Differentiation; Sexual Behavior, Animal; Sexual Maturation; Social Environment; Testosterone | 1991 |
Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Topics: Acid Phosphatase; Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; ErbB Receptors; Estradiol; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 1990 |
Evidence that testosterone modulates in vivo the adenylate cyclase activity in fat cells.
Topics: Adenylyl Cyclases; Adipose Tissue; Androgen Antagonists; Animals; Cricetinae; Female; Imidazoles; Imidazolidines; Male; Orchiectomy; Ovariectomy; Testosterone | 1990 |
Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1990 |
Changes in testis, epididymis and other accessory organs of male rats treated with anandron during sexual maturation.
Topics: Androgen Antagonists; Animals; Epididymis; Genitalia, Male; Glycerylphosphorylcholine; Imidazoles; Imidazolidines; Male; Organ Size; Prostate; Rats; Rats, Inbred Strains; Seminal Vesicles; Sexual Maturation; Spermatogenesis; Testis; Testosterone | 1990 |
Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
Topics: Androgen Antagonists; Carcinoma; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1990 |
Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats.
Topics: Alkaline Phosphatase; Androgen Antagonists; Animals; Body Weight; Dose-Response Relationship, Drug; Epididymis; Estradiol; Fertility; Flutamide; Fructose; Glycerylphosphorylcholine; Imidazoles; Imidazolidines; Leydig Cells; Male; N-Acetylneuraminic Acid; Organ Size; Phospholipids; Prostate; Proteins; Rats; Rats, Inbred Strains; Seminal Vesicles; Sialic Acids; Spermatogenesis; Testis; Testosterone; Urogenital System | 1990 |
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1989 |
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1989 |
Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals--experiences with a novel androgen receptor blocker.
Topics: Adult; Androgen Antagonists; Estradiol; Ethinyl Estradiol; Face; Hair; Humans; Imidazoles; Imidazolidines; Male; Receptors, Androgen; Testosterone; Transsexualism | 1989 |
Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals.
Topics: Adult; Affect; Aggression; Androgen Antagonists; Arousal; Humans; Imidazoles; Imidazolidines; Male; Sex Characteristics; Sexual Behavior; Transsexualism | 1989 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Goserelin; Imidazoles; Imidazolidines; Ketoconazole; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1988 |
Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450.
Topics: Androgen Receptor Antagonists; Animals; Binding, Competitive; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Mice; Microsomes, Liver; Mixed Function Oxygenases; NADP; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Spectrophotometry | 1989 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats; Receptors, Androgen; Testosterone | 1986 |
Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro.
Topics: Aldehyde-Lyases; Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Cytochrome P-450 Enzyme System; Flutamide; Imidazoles; Imidazolidines; Kinetics; Male; Microsomes; Rats; Rats, Inbred Strains; Steroid 17-alpha-Hydroxylase; Steroid Hydroxylases; Testis | 1987 |
The kinetics of antiandrogens in humans.
Topics: Androgen Antagonists; Anilides; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate.
Topics: Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Ethinyl Estradiol; Follicle Stimulating Hormone; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Prolactin; Prostate; Testosterone | 1987 |
ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostate; Radioligand Assay; Rats; Receptors, Androgen; Seminal Vesicles; Testosterone; Tosyl Compounds | 1988 |
Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Topics: Anilides; Animals; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Leuprolide; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Receptors, Androgen | 1988 |
Effects of castration and antiandrogens (RU 23908 and cyproterone acetate) on glandulain activity and on the secretory epithelium of the rat submandibular gland.
Topics: Aminopeptidases; Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Imidazoles; Imidazolidines; Male; Orchiectomy; Rats; Sex Characteristics; Submandibular Gland | 1988 |
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Buserelin; Diethylstilbestrol; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Receptors, Cell Surface; Receptors, LHRH; Receptors, Steroid; Testosterone | 1986 |
Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen.
Topics: Adult; Androgen Antagonists; Estrogens; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Sex Hormone-Binding Globulin; Transsexualism | 1987 |
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Humans; Imidazoles; Imidazolidines; Lipoproteins, HDL; Male; Prostatic Neoplasms | 1987 |
Pulmonary complications of hormone treatment in prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Pulmonary Fibrosis | 1988 |
Merits and considerations in the use of anti-androgen.
Topics: Animals; Castration; Estradiol; Follicle Stimulating Hormone; Humans; Imidazoles; Imidazolidines; Leydig Cells; Luteinizing Hormone; Male; Organ Size; Prolactin; Prostate; Rats; Testis; Testosterone | 1988 |
The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
Topics: Administration, Oral; Androgen Antagonists; Animals; Buserelin; Drug Synergism; Imidazoles; Imidazolidines; Injections, Subcutaneous; Male; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Testis; Testosterone | 1988 |
Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Blood Proteins; Dose-Response Relationship, Drug; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Protein Binding | 1988 |
Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Drug Evaluation, Preclinical; Drug Implants; Estradiol; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Seminal Vesicles; Time Factors | 1988 |
Ocular toxicity of anandron.
Topics: Androgen Antagonists; Dark Adaptation; Humans; Imidazoles; Imidazolidines; Male | 1987 |
Clinical pharmacokinetics of a new antiandrogen Anandron (RU 23908).
Topics: Androgen Antagonists; Carbon Radioisotopes; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Monitoring, Physiologic | 1987 |
Ocular toxicity of Anandron in patients treated for prostatic cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged; Prostatic Neoplasms; Vision Disorders; Visual Acuity | 1986 |
Effectiveness of antiandrogens in the rat.
Topics: Androgen Antagonists; Animals; Flutamide; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Seminal Vesicles; Testosterone | 1986 |
[Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
Topics: Androgens; Animals; Feedback; Hypothalamo-Hypophyseal System; Imidazoles; Imidazolidines; Kinetics; Male; Orchiectomy; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Testis | 1986 |
Pharmacology and clinical studies with RU 23908 (Anandron).
Topics: Androgen Antagonists; Androstenedione; Animals; Castration; Diethylstilbestrol; Flutamide; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Organ Size; Prostate; Prostatic Neoplasms; Rats | 1985 |
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined Modality Therapy; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1984 |
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
Topics: Animals; Buserelin; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Organ Size; Prostate; Rats; Receptors, Cell Surface; Receptors, LH; Seminal Vesicles; Testosterone | 1981 |
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
Topics: Androgen Antagonists; Animals; Buserelin; Drug Therapy, Combination; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats; Testis | 1983 |
New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
Topics: Androgen Antagonists; Animals; Buserelin; Castration; Dihydrotestosterone; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms; Rats; Seminal Vesicles; Testosterone | 1983 |
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testis; Testosterone | 1983 |
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone | 1984 |
Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens.
Topics: Androgen Antagonists; Androgens; Binding, Competitive; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Estrenes; Fibroblasts; Humans; Imidazoles; Imidazolidines; Infant, Newborn; Male; Metribolone; Penis; Receptors, Androgen; Receptors, Steroid; Subcellular Fractions; Testosterone | 1981 |
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats | 1982 |
5 alpha-Dihydrotestosterone-induced uteroglobin synthesis in rabbit uterus is not inhibited by antiandrogen administration but is prevented by estradiol.
Topics: Androgen Antagonists; Animals; Dihydrotestosterone; Estradiol; Female; Glycoproteins; Imidazoles; Imidazolidines; In Vitro Techniques; Rabbits; Receptors, Progesterone; RNA, Messenger; Uteroglobin; Uterus | 1981 |
Anti-androgens in treatment of prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Prostatic Neoplasms | 1995 |
Effect of androgens on the germ cell-depleted testes of prenatally irradiated rats.
Topics: Androgen Antagonists; Androgens; Animals; Base Sequence; Body Weight; DNA Primers; Female; Follicle Stimulating Hormone; Goserelin; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Molecular Sequence Data; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Protein Biosynthesis; Proteins; Rats; Rats, Wistar; RNA; Spermatozoa; Testis; Testosterone | 1995 |
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy].
Topics: Acid Phosphatase; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Recurrence, Local; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Secretory Proteins; Proteins; Seminal Plasma Proteins; Time Factors | 1993 |
Androgens induce divergent proliferative responses in human breast cancer cell lines.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Division; Dihydrotestosterone; Flutamide; Humans; Imidazoles; Imidazolidines; Nandrolone; Oligonucleotides, Antisense; Receptors, Androgen; Tumor Cells, Cultured | 1995 |
Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen.
Topics: Adenosine Triphosphate; Androgen Antagonists; Animals; Carbon Dioxide; Carbon Radioisotopes; Cell Membrane Permeability; Cell Survival; Digitonin; Electron Spin Resonance Spectroscopy; Imidazoles; Imidazolidines; Intracellular Membranes; Liver; Male; Membrane Potentials; Mitochondria, Liver; Oxidation-Reduction; Oxygen Consumption; Palmitic Acid; Palmitic Acids; Rats; Rats, Sprague-Dawley | 1994 |
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Topics: Amino Acid Sequence; Androgen Antagonists; Binding, Competitive; Blotting, Western; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gene Expression Regulation, Viral; Humans; Imidazoles; Imidazolidines; Male; Mammary Tumor Virus, Mouse; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1994 |
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Endocrine Glands; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Pituitary Hormones; Prostatic Neoplasms; Steroids; Testis; Time Factors; Triptorelin Pamoate | 1993 |
[Fatal fulminant hepatitis induced by nilutamide (Anandron)].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Drug Interactions; Humans; Imidazoles; Imidazolidines; Male; Phenobarbital; Prostatic Neoplasms | 1993 |
Pharmacology of nilutamide.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats | 1993 |
Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation.
Topics: Androgen Antagonists; Animals; Binding, Competitive; Blotting, Western; Cell Line; Chloramphenicol O-Acetyltransferase; Chlorocebus aethiops; Cyproterone Acetate; Dihydrotestosterone; DNA; Flutamide; Gene Expression Regulation; Humans; Imidazoles; Imidazolidines; Kidney; Kinetics; Mammary Tumor Virus, Mouse; Metribolone; Receptors, Androgen; Recombinant Proteins; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 1993 |
Upregulation of heparin-affin regulatory peptide by androgen.
Topics: Androgen Antagonists; Animals; Carrier Proteins; Cell Line; Cytokines; Dihydrotestosterone; Gene Expression Regulation; Growth Substances; Humans; Imidazoles; Imidazolidines; RNA, Messenger; Up-Regulation | 1995 |
[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone; Humans; Imidazoles; Imidazolidines; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1996 |
Nilutamide approved for metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 1996 |
[An unusual presentation of prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Humans; Imidazoles; Imidazolidines; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tomography, X-Ray Computed | 1996 |
[Fatal fulminating hepatitis caused by nilutamide. A new case].
Topics: Aged; Androgen Antagonists; Fatal Outcome; Hepatic Encephalopathy; Humans; Imidazoles; Imidazolidines; Male | 1996 |
Antiandrogen monotherapy in the management of advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Prostatic Neoplasms; Tosyl Compounds | 1997 |
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Topics: Androgen Antagonists; Anilides; Animals; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dose-Response Relationship, Drug; Flutamide; Glycoproteins; Humans; Imidazoles; Imidazolidines; Membrane Transport Proteins; Mice; Neoplasm Proteins; Nitriles; Tosyl Compounds; Tumor Cells, Cultured | 1997 |
Antiandrogen withdrawal syndrome with nilutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Humans; Imidazoles; Imidazolidines; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1997 |
Antiandrogen withdrawal syndrome with nilutamide.
Topics: Androgen Antagonists; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Substance Withdrawal Syndrome | 1997 |
Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Cisplatin; Disease Progression; Estrogens; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Karnofsky Performance Status; Lactates; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Orchiectomy; Progesterone Congeners; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate | 1997 |
Comment: clinical experiences of visual disturbances with nilutamide.
Topics: Adaptation, Ocular; Androgen Antagonists; Humans; Imidazoles; Imidazolidines | 1997 |
Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progression; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Treatment Failure | 1998 |
Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders.
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Genital Diseases, Male; Genitalia, Male; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Male; Nitriles; Orchiectomy; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testosterone; Tosyl Compounds | 1998 |
Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Imidazoles; Imidazolidines; Leuprolide; Lung Diseases, Interstitial; Male; Prostatic Neoplasms | 1998 |
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Topics: Amino Acid Substitution; Androgen Antagonists; Androgens; Androstenedione; Animals; beta-Galactosidase; Cell Line; Dihydrotestosterone; Estradiol; Flutamide; Genes, Reporter; Imidazoles; Imidazolidines; Luciferases; Male; Point Mutation; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Transfection | 1997 |
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Binding, Competitive; Breast Neoplasms; Cell Division; Cytosol; Female; Gene Expression Regulation; Humans; Imidazoles; Imidazolidines; Medroxyprogesterone Acetate; Progestins; Receptors, Androgen; Transcription, Genetic; Tritium; Tumor Cells, Cultured | 1999 |
Androgen blockade in prostate cancer.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Orchiectomy; Prostatic Neoplasms | 2000 |
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.
Topics: Amino Acid Substitution; Binding Sites; Binding, Competitive; Crystallography, X-Ray; Flutamide; Humans; Imidazoles; Imidazolidines; Ligands; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Receptors, Androgen; Receptors, Progesterone; Stereoisomerism; Structure-Activity Relationship | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Cell Division; Cell Survival; Culture Media, Serum-Free; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Gene Expression Regulation; Humans; Imidazoles; Imidazolidines; Male; Metribolone; Nitriles; Prostatic Neoplasms; Rats; Receptors, Androgen; Testosterone Congeners; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2001 |
Nilutamide: possible utility as a second-line hormonal agent.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2001 |
Nilutamide-induced neutropenia.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neutropenia; Prostatic Neoplasms | 2001 |
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.
Topics: Anilides; Animals; Cells, Cultured; Flutamide; Haplorhini; Imidazoles; Imidazolidines; Ligands; Nitriles; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Structure-Activity Relationship; Tosyl Compounds; Trail Making Test | 2003 |
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Castration; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure | 2003 |
Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
Topics: Amines; Anaerobiosis; Androgen Antagonists; Animals; Cattle; Electron Spin Resonance Spectroscopy; Free Radicals; Imidazoles; Imidazolidines; Mice; NADP; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Rats; Recombinant Proteins; Time Factors | 2003 |
[Fatal fulminating hepatitis induced by nilutamide].
Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Imidazoles; Imidazolidines; Liver Failure; Male; Prostatic Neoplasms | 2003 |
Distribution of nitroreductive activity toward nilutamide in rat.
Topics: Androgen Antagonists; Animals; Brain; Cells, Cultured; Chromatography, High Pressure Liquid; Cytosol; Imidazolidines; Intestinal Mucosa; Kidney; Liver; Male; Nitroreductases; Rats; Rats, Sprague-Dawley | 2004 |
Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
Topics: Anilides; Binding Sites; Flutamide; Imidazolidines; Ligands; Models, Molecular; Nitriles; Quantitative Structure-Activity Relationship; Receptors, Androgen; Tosyl Compounds | 2005 |
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Buserelin; Clinical Trials, Phase II as Topic; Hemoglobins; Humans; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sickness Impact Profile; Testosterone | 2005 |
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
Topics: Aged; Androgen Antagonists; Cyproterone Acetate; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Time Factors | 2005 |
Androgen receptor activities of p,p'-DDE, fenvalerate and phoxim detected by androgen receptor reporter gene assay.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Biological Assay; Cell Line; Cercopithecus; Dexamethasone; Dichlorodiphenyl Dichloroethylene; Dihydrotestosterone; Genes, Reporter; Humans; Imidazolidines; Insecticides; Mammary Tumor Virus, Mouse; Mice; Nitriles; Organothiophosphorus Compounds; Plasmids; Pyrethrins; Receptors, Androgen; Transfection | 2006 |
[From the finger to the eye!...].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diplopia; Functional Laterality; Humans; Imidazolidines; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Radiography; Sella Turcica; Treatment Outcome | 2005 |
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazolidines; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2005 |
Nontranscriptional regulation of cardiac repolarization currents by testosterone.
Topics: Action Potentials; Androgen Antagonists; Animals; Electrophysiology; Female; Guinea Pigs; Heart Ventricles; Imidazolidines; In Vitro Techniques; Male; Membrane Potentials; Models, Animal; Muscle Cells; Patch-Clamp Techniques; Testosterone; Ventricular Function | 2005 |
Metabolism of nilutamide in rat lung.
Topics: Androgen Antagonists; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytosol; Enzyme Inhibitors; Epithelial Cells; Imidazolidines; In Vitro Techniques; Kinetics; Lung; Macrophages, Alveolar; Male; Mass Spectrometry; Oxidation-Reduction; Rats; Rats, Sprague-Dawley | 2006 |
Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3.
Topics: Androgens; Animals; Base Sequence; Catecholamine Plasma Membrane Transport Proteins; Cells, Cultured; Female; Gene Expression Regulation; Imidazolidines; Kidney; Luciferases; Male; Molecular Sequence Data; Organic Cation Transport Proteins; Organic Cation Transporter 2; Rats; Receptors, Androgen; Sex Characteristics; Testosterone | 2006 |
Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells.
Topics: Androgen Antagonists; Androgens; Animals; Blastocyst; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dihydrotestosterone; Gene Expression Regulation, Developmental; Imidazolidines; Mice; Mice, Inbred ICR; Receptors, Adrenergic; Stem Cells; Testosterone | 2006 |
Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay.
Topics: Androgen Antagonists; Animals; Cell Line; Cell Proliferation; Cell Survival; Dexamethasone; Dihydrotestosterone; Flutamide; Humans; Imidazolidines; Luciferases; Molecular Structure; Nitriles; Permethrin; Pesticides; Pyrethrins; Receptors, Androgen; Recombinant Fusion Proteins; Response Elements; Transfection | 2007 |
Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor.
Topics: Amino Acid Sequence; Androgen Receptor Antagonists; Androstadienes; Aorta; Cells, Cultured; Endothelium, Vascular; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Ginsenosides; Humans; Imidazolidines; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Wortmannin | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Imidazolidines; Male; Models, Molecular; Mutagenesis, Site-Directed; Neoplasms, Hormone-Dependent; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Testosterone; Tosyl Compounds; Transcription, Genetic; Transfection | 2007 |
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Dihydrotestosterone; Drug Resistance, Neoplasm; Drug Synergism; Flutamide; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazolidines; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2007 |
A bifunctional colchicinoid that binds to the androgen receptor.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Colchicine; Cytoplasm; Humans; Imidazolidines; Male; Protein Structure, Secondary; Receptors, Androgen | 2007 |
Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.
Topics: Androgen Antagonists; Anilides; Binding, Competitive; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ferrous Compounds; Humans; Hydantoins; Imidazolidines; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Tosyl Compounds; Tumor Cells, Cultured | 2008 |
Delayed dark adaptation caused by nilutamide.
Topics: Age Factors; Aged, 80 and over; Androgen Antagonists; Carcinoma; Dark Adaptation; Dose-Response Relationship, Drug; Humans; Imidazolidines; Male; Prostatic Neoplasms; Retina; Time Factors; Vision Disorders; Vision, Low | 2008 |
Fulminant hepatic failure due to nilutamide hepatotoxicity.
Topics: Aged; Androgen Antagonists; Fatal Outcome; Humans; Imidazolidines; Liver Failure, Acute; Male | 2009 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2008 |
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Survival Rate | 2009 |
Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway.
Topics: Analysis of Variance; Androgen Antagonists; Androgens; Blotting, Western; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fluorescent Dyes; Humans; Imidazolidines; Immunoprecipitation; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Testosterone; Time Factors; Transfection | 2010 |
Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells.
Topics: Androstadienes; Endothelial Cells; Endothelium; Flavonoids; Humans; Imidazolidines; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Umbilical Veins; Wortmannin | 2010 |
Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice.
Topics: Administration, Oral; Androgen Antagonists; Animals; Anthelmintics; Disease Models, Animal; Female; Imidazolidines; Male; Mice; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni | 2010 |
Anti-androgen effects of cypermethrin on the amino- and carboxyl-terminal interaction of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line; Dihydrotestosterone; Humans; Imidazolidines; Insecticides; Plasmids; Pyrethrins; Receptors, Androgen; Recombinant Proteins; Two-Hybrid System Techniques | 2012 |
Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978.
Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Disease Models, Animal; Humans; Hydantoins; Imidazolidines; Male; Mice; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2014 |
Crucial role of androgen receptor in vascular H2S biosynthesis induced by testosterone.
Topics: Adult; Alkynes; Androgen Antagonists; Animals; Aorta, Thoracic; Female; Glycine; Humans; Hydrogen Sulfide; Imidazolidines; Male; Middle Aged; Rats; Rats, Wistar; Receptors, Androgen; Sex Factors; Testosterone; Vasodilation; Vasodilator Agents | 2015 |
Liquid chromatography electrospray ionization tandem mass spectrometry study of nilutamide and its stress degradation products: in silico toxicity prediction of degradation products.
Topics: Androgen Antagonists; Drug Stability; Humans; Hydrogen-Ion Concentration; Hydrolysis; Imidazolidines; Molecular Structure; Photolysis; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2014 |
Phase I and phase II reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry.
Topics: Chromatography, Liquid; Computer Simulation; Electrochemistry; Glutathione; Imidazolidines; Niclosamide; Nitrophenols; Oxidation-Reduction; Spectrometry, Mass, Electrospray Ionization; Xenobiotics | 2014 |
Identification and Characterization of Androgen-Responsive Genes in Zebrafish Embryos.
Topics: Androgen Antagonists; Androgens; Animals; Embryo, Nonmammalian; Ethinyl Estradiol; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Developmental; Humans; Imidazolidines; Receptors, Androgen; Testosterone; Zebrafish | 2015 |
Lung caught in Nilutamide treatment.
Topics: Aged, 80 and over; Androgen Antagonists; Anticholesteremic Agents; Antineoplastic Agents; Drug Therapy, Combination; Dyslipidemias; Humans; Imidazolidines; Lung; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; Rosuvastatin Calcium | 2016 |
A highly sensitive and selective electrochemical determination of non-steroidal prostate anti-cancer drug nilutamide based on f-MWCNT in tablet and human blood serum sample.
Topics: Androgen Antagonists; Antineoplastic Agents; Biosensing Techniques; Electrochemical Techniques; Electrodes; Humans; Imidazolidines; Limit of Detection; Nanotubes, Carbon; Reproducibility of Results; Tablets | 2017 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
In silico elucidation of novel anticancer lead molecules targeting human prostate specific gene-1 protein.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Adhesion Molecules; Computer Simulation; Humans; Imidazolidines; Molecular Dynamics Simulation; Molecular Targeted Therapy; Protein Structure, Secondary; Structural Homology, Protein; Thermodynamics | 2019 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |
Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin.
Topics: Androgen Antagonists; Deuterium; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Radiochemistry; Structure-Activity Relationship; Tosyl Compounds | 2019 |
A cerium vanadate interconnected with a carbon nanofiber heterostructure for electrochemical determination of the prostate cancer drug nilutamide.
Topics: Antineoplastic Agents; Carbon; Cerium; Electrochemical Techniques; Electrodes; Humans; Hydrogen-Ion Concentration; Imidazolidines; Limit of Detection; Male; Nanofibers; Prostatic Neoplasms; Reproducibility of Results; Vanadates | 2019 |
Echinacoside‑induced nitric oxide production in endothelial cells: Roles of androgen receptor and the PI3K‑Akt pathway.
Topics: Androgen Receptor Antagonists; Cell Line; Endothelial Cells; Glycosides; Human Umbilical Vein Endothelial Cells; Humans; Imidazolidines; Nitric Oxide; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction | 2020 |
Stromal-AR influences the growth of epithelial cells in the development of benign prostate hyperplasia.
Topics: Androgen Antagonists; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Epithelial Cells; Humans; Imidazolidines; Male; Prostatic Hyperplasia; Receptors, Androgen; Signal Transduction; Stem Cells; Stromal Cells; Testosterone Propionate | 2020 |
Analysis of the binding modes of the first- and second-generation antiandrogens with respect to F876L mutation.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Biomarkers, Tumor; Flutamide; Humans; Imidazolidines; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylthiohydantoin; Protein Binding; Protein Conformation; Receptors, Androgen; Structure-Activity Relationship; Thermodynamics; Thiohydantoins | 2021 |
Polymorphic forms of antiandrogenic drug nilutamide: structural and thermodynamic aspects.
Topics: Androgen Antagonists; Crystallization; Density Functional Theory; Imidazolidines; Models, Chemical; Thermodynamics | 2021 |